BMEZ:NYE-BlackRock Health Sciences Trust II (USD)

COMMON STOCK | |

Last Closing

USD 15.77

Change

0.00 (0.00)%

Market Cap

USD 1.65B

Volume

0.16M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-07 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TBB AT&T Inc

N/A

USD 151.28B
PRS Prudential Financial Inc

N/A

USD 44.13B
ALL-PB The Allstate Corporation

N/A

USD 33.97B
SOJC Southern Co

N/A

USD 24.81B
AIZN Assurant Inc

N/A

USD 9.38B
RZB Reinsurance Group of America I..

N/A

USD 8.79B
PCG-PA Pacific Gas and Electric Compa..

N/A

USD 6.42B
PCG-PB Pacific Gas and Electric Compa..

N/A

USD 5.85B
UNMA Unum Group

N/A

USD 5.67B
PCG-PD Pacific Gas and Electric Compa..

N/A

USD 5.30B

ETFs Containing BMEZ

PCEF Invesco CEF Income Compos.. 0.00 % 0.50 %

N/A

USD 0.79B
YYY Amplify High Income ETF 0.00 % 0.50 %

N/A

USD 0.50B

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.65% N/A N/A 63% D
Dividend Return 7.92% N/A N/A 96% N/A
Total Return 15.57% N/A N/A 79% B-
Trailing 12 Months  
Capital Gain 3.41% N/A N/A 32% F
Dividend Return 8.83% N/A N/A 90% A-
Total Return 12.24% N/A N/A 48% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.58% N/A N/A 12% F
Dividend Return -0.40% N/A N/A 23% F
Total Return 6.18% N/A N/A 86% B+
Risk Return Profile  
Volatility (Standard Deviation) 24.21% N/A N/A 43% F
Risk Adjusted Return -1.65% N/A N/A 25% F
Market Capitalization 1.65B N/A N/A 64% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike